Skip to main content

Table 3 Multivariate analysis of Cox proportional hazards model 5-year of OS and PFS for all the enrolled patients (n = 424)

From: Positive effect of HPV status on prognostic value of blood lymphocyte-to-monocyte ratio in advanced cervical carcinoma

Prognostic factors

OS

PFS

Hazard ratio

95 % CI

p value

Hazard ratio

95 % CI

p value

LMR: high versus low

0.337

0.129–0.543

0.001

0.239

0.236–0.593

0.001

HPV DNA status: HR-positive HPV DNA versus non-HR HPV DNA

0.243

0.036–0.535

0.001

0.267

0.054–0.772

0.006

Age: ≤46 versus >46

1.591

1.021–3.627

0.065

2.512

1.001–3.872

0.091

FIGO classification: IIA versus IIB versus IIIA versus IIIB versus IIIB versus IVA

3.486

0.957–5.248

0.035

3.275

0.845–5.328

0.073

pathological type: SCC versus ADC versus ASC versus UDC

2.523

1.093– 4.486

0.013

2.753

1.964–5.359

0.017

Lymph node status classification: positive versus negative

1.375

0.896–3.247

0.073

2.553

1.587–3.439

0.065

Treatment modality: IC + RT versus CCRT versus IC + CCRT

3. 864

3.587–6.339

0.039

2.486

1.987–4.239

0.102

ALC: high versus low

0.394

0.198–0.624

0.027

0.512

0.165–0.928

0.143

AMC: high versus low

1.703

0.138–3.614

0.181

0.982

0.301–2.124

0.713

  1. OS overall survival; PFS progression-free survival; CI confidence interval; LMR lymphocyte-to-monocyte ratio; HPV human papillomavirus; DNA deoxyribonucleic acid; HR high risk; FIGO International Federation of Gynecology and Obstetrics; SCC squamous cell carcinoma; ADC adenocarcinoma; ASC adenosquamous carcinoma, UDC undifferentiated carcinoma; IC inductive chemotherapy; CCRT concurrent chemoradiotherapy; RT radiation therapy; AMC absolute monocyte count; ALC absolute lymphocyte count